Benefits and risks of switching from protease inhibitors to nevirapine with stable background therapy in patients with low or undetectable viral load: a multicentre study.
暂无分享,去创建一个
A. Antinori | V. Tozzi | A. Cingolani | F. Baldini | R. Murri | A. Ammassari | A. Luca | S. Giambenedetto | M. Zaccarelli